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ATGGCCCTGGATCTTCTTTCATCCTACGCTCCTGGCTTGGTCGAAAGCCTGCTAACATGGAA
AGGCGCAGCCGGCTTGGCTGCAGCTGTTGCCCTGGGCTATATTATTATAAGCAACCTTCCTG

GAAGGCAGGTTGCTAAGCCCAGCCTTCTTCAAGTCAGAACTGGTGGCGTCGCCTTCGAGAAG
GTCGCTGAGGTAGTTGCCGACTACAGTGACTCTTACGGGCAAACTGAAAAGGGCGAACTCAT

CGTCAAGGACAACAACAAGATTGTCTCTCTCGCGAATACTTTCTATGACCTCATCACCGATG

GATATGAGTGGGGATGGGGCTCCGGCTTCCACTTCTCTCATAGGCTGCCAGGGATGTCCTTC
AATGCATCTCAGCTGCTCCATGAGTCCCGTATGGCGTCTTTCCTGCGCCTGAAGCCCGGCAT

GCAAGTTCTTGATGTTGGCTGCGGTGTCGGAAACCCTGGCAGAACGGTTGCTGCCTGCAGTG
GAGCAGTGGTGACTGGCATCACCATCAATGCATACCAGATCAAGCGCGCTGAGTTGCACACT
AAGCGGGCGGGCTTGGTAGGATACTTCAAGCCAGTTCAGGGAAACTTCTGCGCGATGCCTTT

CCAAGACAAGAGCTTCGATGCTGCCTTTGCCATGGACTCTACTTGCCATGCCCCCAAGCTGG
AGGATGTGTACTCCGAGGTCTTCCGCGTGTTGAAGCCTGGCGCATACTTTGCAACTTATGAG
TGGGTGTCTACAAAGAACTACGACTCCAACAACCCAGAGCACGTGAAGTGCATGAACAGCAT

CATCCTGGGCAATGGCCTGCCGAACATCAGGAGTTGGAAGCAAGCTGAGGAGGCAGGGAAGA
ACGTGGGTTTCAACCTGCTTACCAGCCTCGACATGGCTACAAACTCCCCCATCGGAAAGCCC

TGGTACTCTGTCCCAGAGCGCATGGTAAACTGGGGCCTGTTCCGTTTCCACAAGGCTTGCAT
TCGCACTGCCTCTACCCTGCATCTGCTGCCGCCAGAATCCTGGAAGTTCTTCTACATCCTTG
CAGAGATGGCCGAGAACCTTGTAAAGGGTGGGCAATGGGACATCTTCACCCCCATGCACTTG
CTGATCTTCCAAAAGCCAGAGTAA
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B. BRAUNII, RACE B GENE FOR A
TRITERPENE METHYLTRANSFERASE
ENZYME AND USES THEREOF

invention. In yet another aspect, the present invention pro
vides a host cell transfected with the aforementioned nucleic
acid molecule or vector.

In another aspect, the present invention provides a method
of producing a methylated triterpene of this invention. The

FIELD OF THE INVENTION

method comprises providing a metabolizable carbon source
to a host cell transfected with a nucleic acid molecule of this

The invention relates to triterpene methyltransferase and
its use in producing methylated triterpenes.

invention that encodes a triterpene methyltransferase under
conditions suf?cient for production of a methylated triter

pene. The method optionally further comprises isolating the

BACKGROUND OF THE INVENTION

methylated triterpene produced by the host cell.
Squalene and botryococcene are related by their putative
biosynthetic origins from the condensation of two famesyl
diphosphate (FPP) molecules, a common biosynthetic inter
mediate found in the mevalonate biosynthetic pathway, and
are known to be synthesized by Bolryococcus braunii, race B,
a fresh water algae (Okada et al., J. Appl. Phycology, 7:
555-559, 1995; Metzger et al., Appl. Microbiol. Biolech., 66:
486-496, 2005). Bolryococcus braunii is known for its ability
to accumulate large amounts of hydrocarbons. In particular B.

Other methods, features and advantages of the present
invention will be or become apparent to one with skill in the

art upon examination of the following detailed descriptions. It
is intended that all such additional methods, features and
advantages be included within this description, be within the
scope of the present invention, and be protected by the accom

panying claims.
BRIEF DESCRIPTION OF THE DRAWINGS

20

braunii race B can accumulate 20-50% its dry weight of
FIG. 1 shows the DNA sequence for the B. braunii triter
pene methyltransferase cDNA SEQ ID NO: 1. The start and

C30-C34 botryococcenes and squalenes.
Squalene, botryococcene and their methylated derivatives
from B. braunii have attracted signi?cant attention because
these molecules are thought to be the progenitors to current

25

braunii triterpene methyltransferase protein, SEQ ID NO: 2.

oil shale deposits (Summons et al., Organic Geochem., 33:
99-109, 2002; Walters et al., AAPG Bulletin, 89: 1239-1244,
2005) and because they are considered promising renewable,
alternative biofuels (Banerjee et al., Crit. Rev. Biolech., 22:
245-279 (2002)). For example, Hillen et al. (Biotech.
Bioeng., 24: 193-205, 1982) previously reported on the cata

FIG. 3 illustrates a comparison of putative SAM (S-adeno

syl methionine) and SMT (sterol methyltransferase speci?c)
binding motifs in sterol methyltransferase genes from a vari
30

with a residual of only 3%. Hence, catalytic hydrolysis (as
performed in standard petroleum re?neries) of these highly
branched, poly-unsaturated triterpenes results in the genera

SEQ ID NO: 14, 15, 16, 17 and 18; N. tabacum SEQ ID NO:
19, 20, 21, 22 and 23; A. lhalina SEQ ID NO: 24, 25, 26, 27;
35

and 28 Z. mays SEQ ID NO: 29, 30, 31, 32; and 33 Osaziva
SEQ ID NO: 34, 35, 36, 37 and 38; S. cerevisiae SEQ ID NO:
39, 40, 41, 42 and 43.
FIG. 4 shows TLC separation of reaction products gener
ated upon incubation of extracts from bacteria over-express

40

ing the TMT gene with (?lled circle symbols) and without
squalene (open circle symbols). Extracts of bacteria trans

45

formed with empty vector (no TMT gene) were also incu
bated under identical conditions with (?lled square symbols)
and without (open square symbols) squalene addition. Reac
tions products extracted from the respective reactions were
separated by reverse phase TLC and the radioactivity associ

tion of hydrocarbon fractions that are chemically equivalent
to those derived from current petroleum deposits and are of
direct utility as fuels for internal combustion engines, as well
as feedstocks for chemical manufacturing (Banerjee et al.,

2002).

ety of plants and Bolryococcus braunii triterpene methyl
transferase. Peptide domain sequences 5'-3' for: B. braunii

lytic cracking of oils extracted from Botryococcus braunii,
primarily the methylated botryococcenes and squalene
derivatives, and observed an overall conversion of 79% of the
oil to combustible fuels under standard cracking conditions.
Overall, 67% of the converted oil was to gasoline grade fuel
(octanes), 15% to aviation turbine fuel, and 15% to diesel fuel

stop codons are shown in bold.
FIG. 2 shows the predicted amino acid sequence for the B.

ated with the indicated zones determined by scintillation

These energy-rich triterpene oils have only been available
from cultures of Bolryococcus braunii, a rather slow growing

counting.

green algae that does not lend itself to large-scale or fermen

FIG. 5 illustrates that methylated squalene formation is
S-adenosylmethionine (SAM) dependent. An extract from

tation type culturing conditions (Casadevall et al., Biolech.
Bioeng., 27: 286-295 (1985)). Thus, there is a need for
improved sources of these energy-rich triterpene oils.

50

bacteria over-expressing the TMT cDNA was incubated with

20 mM squalene and the indicated concentrations of (3H
methyl)-SAM for 30 min before separation of the methylated
squalene products by reverse phase TLC. Zones of the TLC

SUMMARY OF THE INVENTION

plate corresponding to where the methylated squalene
In one aspect, the present invention relates to an isolated

55

polypeptide which is a triterpene methyltransferase, for

example a Bolryococcus braunii triterpene methyltransferase
comprising the amino acid sequence of SEQ ID NO:2 as well
as variants, conservative variants, and fragments thereof.
Another aspect of the present invention relates to an iso
lated nucleic acid molecule that encodes a polypeptide of this

60

invention, e.g., isolated nucleic acid molecule encoding SEQ
ID NO: 2 and conservative variants and fragments thereof
including, e.g., SEQ ID NO: 1.
In another aspect, the present invention provides a vector
comprising a nucleic acid molecule(s) of this invention that

encodes a triterpene methyltransferase polypeptide of this

migrated were scraped into scintillation vials, the radioactiv
ity associated with these zone determined by scintillation
counting and the amount of methylated squalene formed cal
culated on the basis of the radioactivity incorporated.
FIG. 6 shows the time dependency of TMT activity.
FIG. 7 illustrates the pH dependency of TMT activity.
FIG. 8 shows that TMT activity is extract amount depen
dent.

FIG. 9 shows the temperature dependency of TMT activity.
FIG. 10 illustrates the squalene substrate dependency of
65

TMT activity.
FIG. 11 shows the C30 botryococcene dependency of TMT

activity.

US 8,704,040 B2
4

3

economically dif?cult. The compositions and methods

FIG. 12 illustrates the lack of lanosterol substrate depen

dency of TMT activity.

described herein provide a mechanism to overcome these

FIG. 13 demonstrates by SDS-PAGE the IPTG inducible
expression of TMT in E. coli by the accumulation of an

dif?culties.
Described herein are the nucleotide and amino acid
sequences and functional characterization of a triterpene

appropriate sized protein (approximately 120 kD) and the
partial puri?cation of the TMT protein based on a hexa
histidine tag appended to the amino terminus of the NUS

methyltransferase gene which, when expressed in a heterolo

TMT construct.

enzyme activity that catalyzes the successive methylation of
linear triterpene hydrocarbons such as squalene and botryo
coccene, generating branched-chain hydrocarbons. The
encoded methyltransferase activity can methylate squalene,
for example, 1 to 4 times, generating mono-, di-, tri- and
tetra-methylated squalenes derivatives. Botryococcene can
likewise be methylated to form, for example, mono-, di-, tri

gous host such as a bacteria, yeast or plant, provides an

FIG. 14 shows the GC-FID detection of squalene and

methylated squalenes in yeast over-expressing cDNAs for B.

braunii squalene synthase only (A), B. braunii triterpene
methyltransferase only (B), or both squalene synthase and
triterpene methyltransferase (C). Hexane extracts of the yeast
cultures were prepared, concentrated, and analyzed by GC
FID. Compound identi?cation was based on GC retention

and tetra-methylated botryococcenes.

times reported by Achitouv et al. (2004) Phylochemislry, 65:

The identi?cation of the triterpene methyltransferase

3159-3165 (incorporated herein by reference).

nucleic acid molecule and its encoded polypeptide, e.g. a

FIG. 15 shows the GC-MS detection of squalene and

methylated squalene in yeast cultures over-expressing
squalene synthase only (b) or squalene synthase plus triter
pene methyltransferase (a).

20

raw materials for the reliable and cost effective production of
an energy-rich, renewable, and sustainable biofuel source.

FIG. 16 depicts the lack of accumulation of methylated
squalene derivatives in yeast cells over-expressing only the B.
braunii squalene synthase (FIG. 16, panel A) or as compared
to yeast cells expressing both the B. braunii squalene syn

For example, the co-expression of the triterpene methyltrans
25

thase and triterpene methyltransferase genes (FIG. 16, panel
FIG. 17 depicts the accumulation of mono- and di-methy
late squalene in a time dependent manner.
30

DETAILED DESCRIPTION OF THE INVENTION

35

and reagents described, as these may vary. It is also to be
understood that the terminology used herein is intended to

40

methyltransferase from any species may be used, including
an algal triterpene methyltransferase, such as a Botryococcus

braunii triterpene methyltransferase. For example, FIG. 1

claims, the singular forms “a,” “an,” and “the” include plural

shows the DNA sequence encoding a B. braunii triterpene

methyltransferase of this invention (SEQ ID NO: 1), and FIG.
45

2 shows the amino acid sequence of a B. braunii triterpene

methyltransferase of this invention (SEQ ID NO:2). It should
be understood that the invention is not limited to use of

by reference in their entirety for the purpose of describing and

triterpene methyltransferase sequences of SEQ ID NO:l or

disclosing the methodologies, reagents, and tools reported in
the publications that might be used in connection with the

acid molecule encoding a triterpene methyltransferase. In
another aspect, the present invention provides a polypeptide
encoded by a triterpene methyltransferase nucleic acid mol
ecule. A triterpene methyltransferase polypeptide can methy
late a triterpene, e.g., squalene or botryococcene, to generate
a mono-, di-, tri- or tetra-methylated triterpene. A triterpene

describe particular embodiments of the present invention, and

references unless the context clearly dictates otherwise.
Unless de?ned otherwise, all technical and scienti?c terms
used herein have the same meanings as commonly under
stood by one of ordinary skill in the art to which this invention
belongs. All publications cited herein are incorporated herein

metabolic diversion of CO2 ?xed in the process of photosyn
thesis ?owing directly into triterpene biosynthesis and accu
mulation.
Thus, in one aspect the present invention provides a nucleic

Before the present compositions and methods are
described, it is to be understood that the invention is not

is in no way intended to limit the scope of the present inven
tion as set forth in the appended claims.
It must be noted that as used herein and in the appended

ferase in combination with suitable famesyl diphosphate

(FPP) synthase and triterpene synthase in transgenic terres
trial plants could yield a production platform for methylated
triterpenes. These compounds would be derived from the

B).

limited to the particular methodologies, protocols, assays,

polypeptide comprising the sequence set forth in SEQ ID NO:
2 or a variant or fragment thereof having triterpene methyl
transferase activity, provides a means of generating important

SEQ ID N012. That is, any naturally-occurring triterpene
50

methyltransferase may be used, whether derived from B.

invention. Nothing herein is to be construed as an admission

braunii or any other algal or other organism. In addition to

that the invention is not entitled to antedate such disclosure by

naturally-occurring triterpene methyltransferase, synthetic

virtue of prior invention.

variants of SEQ ID NO:l or SEQ ID NO:2 may be employed.
While these variants will be described in more detail below,
it is understood that polypeptides of the invention may con

The present inventors have discovered an improved source

of energy-rich triterpene oils. Among other things, the present

55

inventors provide elucidation of the structural and functional
characteristics of a triterpene methyltransferase gene from

tain one or more modi?ed amino acids. The presence of

Botryococcus braunii. The B. braunii triterpene methyltrans

increasing triterpene methyltransferase catalytic activity or
increasing polypeptide stability. Amino acid(s) are modi?ed,
for example, co-translationally or post-translationally during
recombinant production (e.g., N-linked glycosylation at

modi?ed amino acids may be advantageous in, for example,

ferase can be used to produce methylated linear triterpene

hydrocarbons such as methylated botryococcenes and methy
lated squalenes.
These methylated botryococcenes and squalenes can be

60

NiXiS/T motifs during expression in mammalian cells) or
modi?ed by synthetic means. Accordingly, a “mutant”, “vari

easily converted into high octane fuel for use in combustion
engines. Because of this, B. braunii has attracted much inter
est as a potential renewable fuel source. However, due to its

65

ant” or “modi?ed” protein, enzyme, polynucleotide, gene, or
cell, means a protein, enzyme, polynucleotide, gene, or cell,

slow growing nature and aquatic habitat, cultivation of B.

that has been altered or derived, or is in some way different or

braunii for hydrocarbon production remains technically and

changed, from a parent protein, enzyme, polynucleotide,

US 8,704,040 B2
5

6

gene, or cell. A mutant or modi?ed protein or enzyme is

that up to e.g., 35, 25, 10, 5, 4, 3, 2 or 1 ofthe amino acids of
SEQ ID N012 are conservative amino acid substitutions.

usually, although not necessarily, expressed from a mutant
polynucleotide or gene.

Preferably the polypeptides have triterpene methyltrans

A “parent” protein, enzyme, polynucleotide, gene, or cell,
is any protein, enzyme, polynucleotide, gene, or cell, from

ferase activity, e.g. approximately the level of triterpene
methyltransferase activity of a polypeptide of SEQ ID N01 2,

which any other protein, enzyme, polynucleotide, gene, or
cell, is derived or made, using any methods, tools or tech

or higher than such level.
“Conservative amino acid substitutions” of a particular
sequence refers to the replacement of one amino acid, or
series of amino acids, with essentially identical amino acid or
series of amino acids. One of skill will recognize that indi
vidual substitutions, deletions or additions which alter, add or

niques, and whether or not the parent is itself native or mutant.

A parent polynucleotide or gene encodes for a parent protein
or enzyme.

A “mutation” means any process or mechanism resulting
in a mutant protein, enzyme, polynucleotide, gene, or cell.

delete a single amino acid or a percentage of amino acids in an

This includes any mutation in which a protein, enzyme, poly
nucleotide, or gene sequence is altered, and any detectable
change in a cell arising from such a mutation. Typically, a

encoded sequence result in “conservative variations” where
the alterations result in the deletion of an amino acid, addition

mutation occurs in a polynucleotide or gene sequence, by

of an amino acid, or substitution of an amino acid with a

point mutations, deletions, or insertions of single or multiple
nucleotide residues. A mutation includes polynucleotide

functionally similar amino acid.
Conservative substitution tables providing functionally

alterations arising within a protein-encoding region of a gene
as well as alterations in regions outside of a protein-encoding
sequence, such as, but not limited to, regulatory or promoter
sequences. A mutation in a gene can be “silent”, i.e., not

20

Serine (S), and Threonine (T). Another conservative substi
tution group includes Aspartic acid (D) and Glutamic acid
(E). Another conservative substitution group includes Aspar
agine (N) and Glutamine (Q). Yet another conservative sub

re?ected in an amino acid alteration upon expression, leading
to a “sequence-conservative” variant of the gene. This gener
ally arises when one amino acid corresponds to more than one
codon.
Non-limiting examples of a modi?ed amino acid include a

25

tive substitution group includes Phenylalanine (F), Tyrosine

(Y), and Tryptophan (W).

(e. g., farnesylated, geranylgeranylated) amino acid, an acety
30

tions of a percentage, typically less than 15% or less than
10%, of the amino acids of the polypeptide sequence, with an

adequate to guide one of skill in the modi?cation of amino

acids are replete throughout the literature. Example protocols
35

amino acid of the same conservative substitution group.
Accordingly, a conservatively substituted variation of a

polypeptide of the invention can contain, for example, sub
stitutions ofe.g., 40, 35, 25, 10, 5, 4, 3, 2 or 1 amino acidwith

(Humana Press, Towata, N.J.).
Recombinant methods for producing and isolating modi
?ed triterpene methyltransferase polypeptides of the inven

an amino acid of the same conservative substitution group.

tion are described herein. In addition to recombinant produc

tion, the polypeptides may be produced by direct peptide
synthesis using solid-phase techniques (e.g., Stewart et al.
(1969) Solid-Phase Peptide Synthesis (WH Freeman Co, San

Thus, “conservative amino acid substitutions” of a listed

polypeptide sequence (e.g., SEQ ID N012) include substitu

phosphorylated amino acid, and the like. References
are found in Walker (1998) Protein Protocols on CD-ROM

stitution group includesArginine (R) and Lysine (K). Another
conservative substitution group includes Isoleucine, (I) Leu
cine (L), Methionine (M), and Valine (V). Another conserva

glycosylated amino acid, a sulfated amino acid, a prenlyated
lated amino acid, an acylated amino acid, a pegylated amino
acid, a biotinylated amino acid, a carboxylated amino acid, a

similar amino acids are well known in the art. For example,
one conservative substitution group includes Alanine (A),

40

It is understood that the addition of sequences that do not
alter the encoded activity of a nucleic acid molecule, such as
the addition of a non-functional or non-coding sequence, is a

conservative variation of the basic nucleic acid molecule. The
“activity” of an enzyme is a measure of its ability to catalyze
a reaction, i.e., to “function”, and may be expressed as the rate

Francisco); and Merri?eld (1963) J. Am. Chem. Soc. 851

2149-2154; each of which is incorporated by reference). Pep
tide synthesis may be performed using manual techniques or
by automation. Automated synthesis may be achieved, for

at which the product of the reaction is produced. For example,
enzyme activity can be represented as the amount of product
produced per unit of time or per unit of enzyme (e.g., con

example, using Applied Biosystems 431A Peptide Synthe
sizer (Perkin Elmer, Foster City, Calif.) in accordance with
the instructions provided by the manufacturer.

centration or weight), or in terms of af?nity or dissociation

constants. As used interchangeably herein a “triterpene meth
50

yltransferase activity”, “biological activity of triterpene

catalyzes or promotes, more or less speci?cally, one or more 55

methyltransferase” or “functional activity of triterpene meth
yltransferase”, refers to an activity exerted by a triterpene
methyltransferase protein, polypeptide or nucleic acid mol
ecule on a triterpene methyltransferase polypeptide substrate,
as determined in vivo, or in vitro, according to standard tech

chemical or biochemical reactions. The term “enzyme” can

niques.

also refer to a catalytic polynucleotide (e.g., RNA or DNA).A

One of skill in the art will appreciate that many conserva
tive variations of the nucleic acid constructs which are dis

A “protein” or “polypeptide”, which terms are used inter
changeably herein, comprises one or more chains of chemical

building blocks called amino acids that are linked together by
chemical bonds called peptide bonds. An “enzyme” means

any substance, composed wholly or largely of protein, that

“native” or “wild-type” protein, enzyme, polynucleotide,

closed herein yield a functionally identical construct. For

gene, or cell, means a protein, enzyme, polynucleotide, gene,
or cell that occurs in nature.

60

Accordingly, this invention also provides in various
embodiments, isolated or recombinant polypeptides compris

example, owing to the degeneracy of the genetic code, “silent

99% identical to the full-length amino acid sequence of SEQ

substitutions” (i.e., substitutions in a nucleic acid sequence
which do not result in an alteration in an encoded polypep
tide) are an implied feature of every nucleic acid sequence
which encodes an amino acid. Similarly, “conservative amino
acid substitutions,” in one or a few amino acids in an amino
acid sequence are substituted with different amino acids with

ID N012, and polypeptides comprising SEQ ID N01 2 except

highly similar properties, are also readily identi?ed as being

ing the amino acid sequence set forth in SEQ ID N012, an
amino acid sequence that is at least 20%, 30%, 33%, 35%,

37%, 40%, 44%, 50%, 53%, 60%, 70%, 80%, 90%, 95% and

65
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highly similar to a disclosed construct. Such conservative
variations of each disclosed sequence are a feature of the

A polynucleotide, polypeptide, or other component is “iso
lated” when it is partially or completely separated from com

polypeptides provided herein.

ponents with which it is normally associated (other proteins,
nucleic acid molecules, cells, synthetic reagents, etc.). A

It will be appreciated by those skilled in the art that due to
the degeneracy of the genetic code, a multitude of nucleotide

nucleic acid molecule or polypeptide is “recombinant” when
it is arti?cial or engineered, or derived from an arti?cial or

sequences encoding modi?ed triterpene methyltransferase

engineered protein or nucleic acid molecule. For example, a

polypeptides of the invention may be produced, some of
which bear substantial identity to the nucleic acid sequences

polynucleotide that is inserted into a vector or any other
heterologous location, e.g., in a genome of a recombinant
organism, such that it is not associated with nucleotide

explicitly disclosed herein. For instance, codons AGA, AGG,
CGA, CGC, CGG, and CGU all encode the amino acid argi

sequences that normally ?ank the polynucleotide as it is
found in nature is a recombinant polynucleotide. A protein
expressed in vitro or in vivo from a recombinant polynucle
otide is an example of a recombinant polypeptide. Likewise,
a polynucleotide sequence that does not appear in nature, for
example a variant of a naturally occurring gene, is recombi

nine. Thus, at every position in the nucleic acid molecules of
the invention where an arginine is speci?ed by a codon, the
codon can be altered to any of the corresponding codons

described above without altering the encoded polypeptide. It
is understood that U in an RNA sequence corresponds to T in
a DNA sequence.

nant. For example, an “isolated” nucleic acid molecule is one

“Conservative variants” are proteins or enzymes in which a

which is separated from other nucleic acid molecules which

given amino acid residue has been changed without altering
overall conformation and function of the protein or enzyme,
including, but not limited to, replacement of an amino acid
with one having similar properties, including polar or non

are present in the natural source of the nucleic acid molecule.
20

For example, with regards to genomic DNA, the term “iso

25

lated” includes nucleic acid molecules which are separated
from the chromosome with which the genomic DNA is natu
rally associated. Typically, an “isolated” nucleic acid mol
ecule is free of sequences which naturally ?ank the nucleic
acid molecule (i.e., sequences located at the 5' and 3' ends of

polar character, size, shape and charge. Amino acids other
than those indicated as conserved may differ in a protein or
enzyme so that the percent protein or amino acid sequence

similarity between any two proteins of similar function may
vary and can be, for example, at least 30%, at least 32%, at
least 37%, at least 44%, at least 50%, at least 53%, at least
70%, at least 80%, at least 90%, at least 95%, at least 98% or
at least 99%, as determined according to an alignment

the nucleic acid molecule) in the genomic DNA of the organ
ism from which the nucleic acid molecule is derived. For

example, in various embodiments, the isolated nucleic acid
molecule can contain less than about 5 kb, 4 kb, 3 kb, 2 kb, 1
30

scheme. As referred to herein, “sequence similarity” means

kb, 0.5 kb or 0.1 kb of nucleotide sequences which naturally
?ank the nucleic acid molecule in genomic DNA of the cell

the extent to which nucleotide or protein sequences are
related. The extent of similarity between two sequences can

from which the nucleic acid molecule is derived. Moreover,

be based on percent sequence identity and/or conservation.
“Sequence identity” herein means the extent to which two

ecule, can be substantially free of other cellular material, or

an “isolated” nucleic acid molecule, such as a cDNA mol
35

culture medium when produced by recombinant techniques,

nucleotide or amino acid sequences are invariant. “Sequence
alignment” means the process of lining up two or more

or substantially free of chemical precursors or other chemi

sequences to achieve maximal levels of identity (and, in the

In some embodiments, a polypeptide provided herein
includes amino acid residue substitutions that correspond to

cals when chemically synthesized.

case of amino acid sequences, conservation) for the purpose

of assessing the degree of similarity. Numerous methods for
aligning sequences and assessing similarity/identity are
known in the art such as, for example, the Cluster Method,
wherein similarity is based on the MEGALIGN algorithm, as
well as BLASTN, BLASTP, and FASTA (Lipman and Pear
son, 1985 Science 22; 227(4693):1435-41; Pearson and Lip
man, 1988 Proc Natl Acad Sci USA, 85(8):2444-8). When
using all of these programs, the preferred settings are those

40

98 or 99% of the time. In other words, the invention encom

passes polypeptides that contain the recited amino acid sub
stitutions at 80%, 85%, 90%, 95, 98 or 99% of the recited
positions in a given sequence. The skilled artisan will recog
45

that results in the highest sequence similarity.
Non-conservative modi?cations of a particular polypep
tide are those which substitute any amino acid not character
ized as a conservative substitution. For example, any substi
tution which crosses the bounds of the six groups set forth
above. These include substitutions of basic or acidic amino

positions in a particular sequence at least 80%, 85%, 90%, 95,

50

nize that not every substitution from a group of substitutions
is necessary to obtain a modi?ed polypeptide that is active on
a triterpene substrate.
“Sequence identity” herein means the extent to which two
nucleotide or amino acid sequences are invariant. “Sequence
alignment” means the process of lining up two or more

sequences to achieve maximal levels of identity (and, in the
case of amino acid sequences, conservation) for the purpose

of assessing the degree of similarity. Numerous methods for
aligning sequences and assessing similarity/ identity are

acids for neutral amino acids, (e.g., Asp, Glu, Asn, or Gln for
any other substitution not replacing an amino acid with a like

known in the art such as, for example, the Cluster Method,
wherein similarity is based on the MEGALIGN algorithm, as
well as BLASTN, BLASTP, and FASTA (Lipman and Pear

amino acid. Basic amino acids include lysine (K), arginine
(R), histidine (H); acidic amino acids include aspartic acid

these programs, the preferred settings are those that results in

Val, Ile, Leu or Met), aromatic amino acid for basic or acidic

55

amino acids (e.g., Phe, Tyr or Trp for Asp, Asn, Glu or Gln) or

(D), glutamic acid (E); uncharged polar amino acids include

son, 1985; Pearson and Lipman, 1988). When using all of
60

glycine (G), asparagine (N), glutamine (Q), serine (S), threo
nine (T), tyrosine (Y), cysteine (C); nonpolar amino acids

the highest sequence similarity. For example, the “identity” or
“percent identity” with respect to a particular pair of aligned
amino acid sequences can refer to the percent amino acid

include alanine (A), valine (V), leucine (L), isoleucine (I),

sequence identity that is obtained by ClustalW analysis (ver

proline (P), phenylalanine (F), methionine (M), tryptophan

sion W 1.8 available from European Bioinformatics Institute,
Cambridge, UK, counting the number of identical matches in
the alignment and dividing such number of identical matches

(W); beta-branched amino acids include threonine (T), valine
(V), isoleucine (I); aromatic amino acids include tyrosine

(Y), phenylalanine (F), tryptophan (W), histidine (H).
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by the greater of (i) the length of the aligned sequences, and
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(ii) 96, and using the following default ClustalW parameters
to achieve slow/accurate pairwise alignments4Gap Open
Penalty: 10; Gap Extension Penalty: 0.10; Protein weight
matrix: Gonnet series; DNA weight matrix: IUB; Toggle
Slow/Fast pairwise alignmentsISLOW or FULL Alignment.

in the reference sequence. In the case of truncations or fusions
there can be stretches of amino acids in either the reference or

aligned sequence that do not correspond to any amino acid in

the corresponding sequence.
Also contemplated are fragments of the full length triter

pene methyltransferase polypeptides and polynucleotides,
e.g., fragments of polypeptides, wherein the polypeptide

See also Larkin M A, Blackshields G, Brown N P, Chema R,
McGettigan P A, McWilliam H, Valentin E, Wallace I M,
Wilm A, LopeZ R, Thompson J D, Gibson T J, Higgins D G.
(2007). Clustal W and Clustal X version 2.0. Bioinformalics,

comprises the amino acid sequence set forth in SEQ ID NO:
2 and fragments of nucleic acid molecules, wherein the
nucleic acid molecules comprises the sequence set forth in
SEQ ID NO: 1. For example a fragment of this invention is a
fragment of SEQ ID NO: 2 or SEQ ID NO: 1 comprising the
SMT-II domain, SEQ ID NO:17, or encoding the SMT-II
domain. A “fragment” is a unique portion of a triterpene

23, 2947-2948.)
Two sequences are “optimally aligned” when they are

aligned for similarity scoring using a de?ned amino acid
substitution matrix (e.g., BLOSUM62), gap existence pen
alty and gap extension penalty so as to arrive at the highest
score possible for that pair of sequences. Amino acid substi
tution matrices and their use in quantifying the similarity

methyltransferase polypeptide or the polynucleotide encod
ing triterpene methyltransferase which is identical in
sequence to, but shorter in length than, the parent sequence. A
fragment may comprise up to the entire length of the de?ned

between two sequences are well-known in the art and

described, e.g., in Dayhoff (1978) “A model of evolutionary
change in proteins” in “Atlas of Protein Sequence and Struc
ture,”Vol. 5, Suppl. 3 (ed. M. O. Dayhoff), pp. 345-352. Natl.
Biomed. Res. Found, Washington, DC. and Henikoff et al.
(1992) Proc. Natl. Acad. Sci. USA 89: 10915-10919 (each of
which is incorporated in its entirety by reference). The BLO

sequence, minus one nucleotide/amino acid residue. For
20

ous nucleotides or amino acid residues of a given nucleic acid

molecule or polypeptide. A fragment used as a probe, primer,
antigen, catalytic molecule, or for other purposes, may be at

SUM62 matrix is often used as a default scoring substitution

matrix in sequence alignment protocols such as Gapped
BLAST 2.0. The gap existence penalty is imposed for the

least 5, 10, 15, 16, 20, 25, 30, 40, 50, 60, 75, 100, 150, 250 or
25

30

selected from the ?rst 250 or 500 amino acids (or ?rst 25% or
50%) of a polypeptide as shown in a certain de?ned sequence.

Clearly these lengths are exemplary, and any length that is

supported by the speci?cation, including the Sequence List
ing, tables, and ?gures, may be encompassed by the present

in one or both sequences so as to arrive at the highest possible

score. While optimal alignment and scoring can be accom
plished manually, the process is facilitated by the use of a

at least 500 contiguous nucleotides or amino acid residues in

length. Fragments may be preferentially selected from certain
regions of a molecule. For example, a polypeptide fragment
may comprise a certain length of contiguous amino acids

introduction of a single amino acid gap in one of the aligned

sequences, and the gap extension penalty is imposed for each
additional empty amino acid position inserted into an already
opened gap. The alignment is de?ned by the amino acids
positions of each sequence at which the alignment begins and
ends, and optionally by the insertion of a gap or multiple gaps

example, a fragment may comprise from 5 to 1000 contigu

35

embodiments.
Also contemplated in this invention are isolated polypep

computer-implemented alignment algorithm, e.g., gapped

tides that are methyltransferases, preferably triterpene meth

BLAST 2.0, described in Altschul et al. (1997) Nucl. Acids

yltransferases, that comprise 5 peptide domains, each peptide

Res. 25: 3389-3402 (incorporated by reference herein), and

domain comprising at least 9 amino acids, wherein three of
the domains, SAM-I, SAM-II and SAM-III, are associated
with binding of a common methyl donor (SAM binding
domains), and two peptide domains, SMT-I and SMT-II, are
associated with catalytic transfer of methyl substituents from
a methyl donor to a methyl acceptor. The SMT-I, SAM-I,
SAM-II, SMT-II and SAM-III domains of the triterpene
methyltransferases of this invention may comprise respec

made available to the public at the National Center for Bio

technology Inforrnation (NCBI) Website (www.ncbi.nlm.ni

40

h.gov). Optimal alignments, including multiple alignments,
can be prepared using, e.g., PSI-BLAST, available through
the NCB1 website and described by Altschul et al. (1997)
Nucl. Acids Res. 25:3389-3402 (incorporated by reference

herein).

45

With respect to an amino acid sequence that is optimally
aligned with a reference sequence, an amino acid residue

tively, e.g., SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16,
SEQ ID NO: 17 and SEQ ID NO: 18 (See FIG. 3, the 5

“corresponds to” the position in the reference sequence with
which the residue is paired in the alignment. The “position” is
denoted by a number that sequentially identi?es each amino

domains of B. braunii). In an embodiment of the invention,
the SMT-I domain comprises an amino acid sequence that is
50

at least 20%, 30%, 40%, 50%, 60%, 62%, 70%, 77%, 80%,

acid in the reference sequence based on its position relative to
the N-tenninus. For example, in SEQ ID NO:2 as the refer

90% or 95% identical to the full-length of SEQ ID NO: 14, the
SAM-I domain comprises an amino acid sequence that is at

ence sequence, position 1 is M, position 2 isA, position 3 is L,

least 20%, 30%, 38%, 40%, 50%, 60%, 63%, 70%, 78%,

etc. When a test sequence is optimally aligned with SEQ ID
NO:2, a residue in the test sequence that aligns with the L at
position 3 is said to “correspond to position 3” of SEQ ID

55

NO:2. Owing to deletions, insertion, truncations, fusions,
etc., that must be taken into account when determining an

optimal alignment, in general the amino acid residue number
in a test sequence as determined by simply counting from the

60

N-terminal will not necessarily be the same as the number of

its corresponding position in the reference sequence. For
example, in a case where there is a deletion in an aligned test
sequence, there will be no amino acid that corresponds to a

position in the reference sequence at the site of deletion.
Where there is an insertion in an aligned reference sequence,

that insertion will not correspond to any amino acid position

65

80%, 89%, 90% or 95% identical the full-length of SEQ ID
NO: 15, the SAM-II peptide domain may comprises an amino
acid sequence that is at least 20%, 30%, 40%, 50%, 60%,
63%, 70%, 80%, 90% or 95% identical to the full-length of
SEQ ID NO: 16, the SMT-II peptide domain comprises an
amino acid sequence that is at least 20%, 30%, 40%, 50%,
60%, 70%, 80%, 90% or 95% identical to the full-length of
SEQ ID NO: 17 and the SAM-III peptide domain comprises
an amino acid sequence that is at least 20%, 30%, 40%, 50%,
60%, 70%, 80%, 90% or 95% identical the full-length ofSEQ
ID NO: 18. The SMT-II peptide domain may also comprise an
amino acid sequence that is at least 20%, 30%, 40%, 50%,
60%, 63%, 70%, 80%, 90% or 95% identical to the full-length
of SEQ ID NO: 16, with the proviso that the sequence does

US 8,704,040 B2
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not comprise amino acid sequence IEATCHAP (SEQ ID NO:

With desirable functional properties (e.g., high kcat or kcat/
Km, low Km, high stability towards heat or other environ
mental factors, high transcription or translation rates, resis

22). The 5 peptide domains may be present in the methyl
transferase in any order, preferably the order of the 5 peptides
in the polypeptide is, from its amino to carboxy terminal,
SMT-I, SAM-I, SAM-II, SMT-II and SAM-III, and more
preferably the SMT-I, SAM-I, SAM-II, SMT-II and SAM-III

tance to proteolytic cleavage, etc.).

Triterpene methyltransferase polynucleotides of this
invention, including nucleotide sequences that encode triter

peptide domains comprise respectively the B. braunii
sequences in FIG. 3, SEQ ID NO: 14, SEQ ID NO: 15, SEQ

pene methyltransferase polypeptides and variants thereof,

ID NO: 16, SEQ ID NO: 17 and SEQ ID NO: 18.

related fusion proteins, or functional equivalents thereof, are
used in recombinant DNA molecules that direct the expres

fragments of triterpene methyltransferase polypeptides,

In other embodiments, isolated nucleic acid molecules are

provided. In one aspect, the invention provides a novel family

sion of the triterpene methyltransferase polypeptides in

of isolated or recombinant polynucleotides referred to herein

appropriate host cells, such as plant cells. Due to the inherent

as “triterpene methyltransferase polynucleotides” or “triter

degeneracy of the genetic code, other nucleic acid sequences

pene methyltransferase nucleic acid molecules.” Triterpene
methyltransferase polynucleotide sequences are character
ized by the ability to encode a triterpene methyltransferase
polypeptide. In general, the invention includes any nucleotide
sequence that encodes any of the novel triterpene methyl

Which encode substantially the same or a functionally equiva
lent amino acid sequence can also be used to clone and

transferase polypeptides described herein. The invention pro
vides nucleic acid molecules encoding a triterpene methyl

express the triterpene methyltransferase polynucleotides.
The term “host cell”, as used herein, includes any cell type
Which is susceptible to transformation With a nucleic acid
construct. The term “transformation” means the introduction
20

of a foreign (i.e., extrinsic or extracellular) gene, DNA or
RNA sequence to a host cell, so that the host cell Will express
the introduced gene or sequence to produce a desired sub
stance, typically a protein or enzyme coded by the introduced

25

include regulatory or control sequences, such as start, stop,

transferase having the sequence set forth in SEQ ID NO: 2 or
conservative variants thereof. In particular the invention pro

vides nucleic acid molecules comprising SEQ ID NO: 1. The
invention also provides isolated or recombinant polynucle
otides that encode the polypeptide domains described herein.
The terms “polynucleotide,” “nucleotide sequence,” and

gene or sequence. The introduced gene or sequence may

“nucleic acid molecule” are used to refer to a polymer of

promoter, signal, secretion, or other sequences used by the
genetic machinery of the cell. A host cell that receives and

nucleotides (A, C, T, U, G, etc. or naturally occurring or

expresses introduced DNA or RNA has been “transformed”

and is a “transforrnant” or a “clone.” The DNA or RNA
resentation thereof, e.g., a character string, etc., depending on 30 introduced to a host cell can come from any source, including

arti?cial nucleotide analogues), e. g., DNA or RNA, or a rep

the relevant context. A given polynucleotide or polynucle

cells of the same genus or species as the host cell, or cells of
a different genus or species.
As Will be understood by those of skill in the art, it can be

otide complementary to the entire length of a given poly
nucleotide can be determined from any speci?ed nucleotide
sequence.

In one aspect, the triterpene methyltransferase polynucle

35

With 64 possible codons, but most organisms preferentially

otides comprise recombinant or isolated forms of naturally
occurring nucleic acid molecules isolated from an organism,

e.g., an algae strain. Exemplary triterpene methyltransferase
polynucleotides include those that encode the Wild-type
polypeptide set forth in SEQ ID N012. In another aspect of the

use a subset of these codons. The codons that are utilized most

often in a species are called optimal codons, and those not
utilized very often are classi?ed as rare or low-usage codons
40

invention, triterpene methyltransferase polynucleotides are

“codon optimization” or “controlling for species codon bias.”

Optimized coding sequences containing codons preferred
45

attributes, e.g., increased catalytic function, increased stabil
ity, or higher expression level, than a triterpene methyltrans
ferase polynucleotide used as a substrate or parent in the
diversi?cation process.
The polynucleotides of the invention have a variety of uses

(see, e.g., Zhang et al. (1991) Gene 105161-72; incorporated
by reference herein). Codons can be substituted to re?ect the
preferred codon usage of the host, a process sometimes called

produced by diversifying, e.g., mutating a naturally occur
ring, isolated, or recombinant triterpene methyltransferase
polynucleotide. It is possible to generate diversi?ed triterpene

methyltransferase polynucleotides encoding triterpene meth
yltransferase polypeptides With superior functional

advantageous to modify a coding sequence to enhance its
expression in a particular host. The genetic code is redundant

by a particular prokaryotic or eukaryotic host (see also, Mur
ray et al. (1 989) Nucl. Acids Res. 17:477-508; incorporated by
reference herein) can be prepared, for example, to increase
the rate of translation or to produce recombinant RNA tran

50

scripts having desirable properties, such as a longer half-life,
as compared With transcripts produced from a non-optimized
sequence. Translation stop codons can also be modi?ed to

in, for example recombinant production (i.e., expression) of
the triterpene methyltransferase polypeptides of the invention

re?ect host preference. For example, preferred stop codons

and as substrates for further diversity generation, e. g., recom
bination reactions or mutation reactions to produce neW and/

tively. The preferred stop codon for monocotyledonous plants

for S. cerevisiae and mammals are UAA and UGA, respec
55

is UGA, Whereas insects and E. coli prefer to use UAA as the

or improved triterpene methyltransferase homologues, and

stop codon (Dalphin et al. (1996) Nucl. Acids Res. 24: 216

the like.
It is important to note that certain speci?c, substantial and

218; incorporated by reference herein). Methodology for
optimizing a nucleotide sequence for expression in a plant is
provided, for example, in US. Pat. No. 6,015,891, and the

credible utilities of triterpene methyltransferase polynucle
otides do not require that the polynucleotide encode a

60

polypeptide With substantial triterpene methyltransferase

references cited therein, (incorporated herein by reference).
“Silent variations” are one species of “conservative varia
tions.” One of skill Will recognize that each codon in a nucleic

activity or even variant triterpene methyltransferase activity.

For example, triterpene methyltransferase polynucleotides

acid sequence (except AUG, Which is ordinarily the only

that do not encode active enzymes can be valuable sources of

codon for methionine) can be modi?ed by standard tech
niques to encode a functionally identical polypeptide.
Accordingly, each silent variation of a nucleic acid sequence
that encodes a polypeptide is implicit in any described

parental polynucleotides for use in diversi?cation procedures
to arrive at triterpene methyltransferase polynucleotide vari
ants, or non-triterpene methyltransferase polynucleotides,
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